Ritter Pharmaceuticals

Pioneering the future of gut health with novel microbiome modulators for impactful patient outcomes.

Founded 2004 Post-IPO Equity Total: $25.73M Biotechnology, Health Care +2

Ritter Pharmaceuticals is a biotechnology company founded in 2004 with a focus on pioneering the future of gut health. The company's slogan, "Pioneering the future of gut health with novel microbiome modulators for impactful patient outcomes," reflects its commitment. Ritter Pharmaceuticals is dedicated to creating innovative therapeutic products that target inflammatory, gastrointestinal, and metabolic diseases by influencing the human gut microbiome. The company's research revolves around examining the metabolic functions of gut microbiota and translating the benefits of prebiotic-based therapeutics into reliable health applications. Ritter Pharmaceuticals has a lineup of unique microbiome modulators that selectively promote the growth of beneficial bacteria in the colon, thereby significantly improving a patient's health. One of their leading therapies, RP-G28, is in development as a treatment for lactose intolerance and has the potential to become the first FDA-approved drug for this condition, which affects over 1 billion people globally. In a Phase 2 clinical trial, RP-G28 has shown promise and is identified as a first-of-its-kind compound, positioning it as a potentially game-changing treatment option. Ritter Pharmaceuticals' last investment amounted to $10.00M in Post-IPO Equity, secured on 21 December 2015, with Aspire Capital Partners, LLC as the investors. With its focus on transformative therapies and a unique approach to gut health, Ritter Pharmaceuticals is poised for significant impact in the biotechnology, healthcare, pharmaceutical, and robotics industries.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Equity	$10.00M	1	Aspire Capital Partners, LLC	21 Dec 2015
Venture Round	$3.69M	-		09 Dec 2014
Venture Round	$1.57M	-		21 Nov 2013
Venture Round	$5.80M	-		02 Aug 2012
Debt Financing	$526.45K	-		14 Feb 2012
Venture Round	$1.95M	1	Javelin Venture Partners	22 Nov 2010
Grant	$244.48K	-		02 Nov 2010
Debt Financing	$452.57K	-		15 Mar 2010
Venture Round	$1.00M	1	Javelin Venture Partners	19 Aug 2009
Venture Round	$500.00K	-		17 Mar 2009

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

$10.00M

Aspire Capital Partners, LLC

21 Dec 2015

Venture Round

$3.69M

09 Dec 2014

Venture Round

$1.57M

21 Nov 2013

Venture Round

$5.80M

02 Aug 2012

Debt Financing

$526.45K

14 Feb 2012

Venture Round

$1.95M

Javelin Venture Partners

22 Nov 2010

Grant

$244.48K

02 Nov 2010

Debt Financing

$452.57K

15 Mar 2010

Venture Round

$1.00M

Javelin Venture Partners

19 Aug 2009

Venture Round

$500.00K

17 Mar 2009

FAQ About Ritter Pharmaceuticals

Pioneering the future of gut health with novel microbiome modulators for impactful patient outcomes.

Ritter Pharmaceuticals was founded in 2004.

Ritter Pharmaceuticals operates in Biotechnology, Health Care, Pharmaceutical and Robotics. Its work centres on microbiome modulators, gut health, therapeutic products and prebiotic-based therapeutics.

Ritter Pharmaceuticals has completed 10 funding rounds, raising a total of $25.73M. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to Ritter Pharmaceuticals include Second Genome Inc., Osprey Pharmaceuticals USA, Cogent Biosciences, PharmaBiome AG. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Ritter Pharmaceuticals and Second Genome Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Ritter Pharmaceuticals

Funding Rounds & Investors (10)

Ritter Pharmaceuticals Alternatives & Competitors

FAQ About Ritter Pharmaceuticals